AMER SPORTS INC
ASNYSETrading Snapshot
- Day Range
- $27.80 – $28.47
- 52-Week Range
- $26.10 – $42.76
- Volume (shares)
- 4,451,200
- Avg Volume (shares)
- —
- Shares Outstanding
- 581.8M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- $6.57B
- Last Q Revenue
- $1.63B
- P/E Ratio
- 29.0
- P/S Ratio
- 2.2x
- EPS (TTM)
- $0.94
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.5%
AMER SPORTS INC
ASAbout AMER SPORTS INC
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach covers Europe, the Middle East, Africa, the Americas, China, and the wider Asia Pacific region. Its operations are structured into three main divisions. The Technical Apparel segment focuses on high-performance outdoor wear, shoes, and accessories, primarily under the Arc'teryx and Peak Performance brands. The Outdoor Performance segment supplies a variety of outdoor apparel, footwear, accessories, and winter sports gear from labels such as Salomon, Atomic, Armada, and ENVE. Finally, the Ball & Racquet Sports segment delivers sports equipment, activewear, and accessories, featuring prominent brands like Wilson, DeMarini, Louisville Slugger, EvoShield, and ATEC. Beyond these brand-specific offerings, Amer Sports' product range includes specialized items like climbing gear, hiking and running shoes, skiing and snowboarding equipment, functional athletic apparel, and lifestyle footwear. They also provide sporting goods for popular activities such as tennis, baseball, American football, basketball, golf, and many other professional and recreational sports. The company's products are distributed through a diverse network that encompasses its own retail stores, major sporting goods retailers, specialty shops, independently operated partner stores, and various distributors. Furthermore, sales are conducted online via their proprietary e-commerce platforms, as well as through retailer-owned and third-party e-commerce sites. Established in 1950 and headquartered in Helsinki, Finland, the company was previously known as Amer Sports Management Holding (Cayman) Limited, officially changing its name to Amer Sports, Inc. in August 2023.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates

ASO vs. AS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Leisure and Recreation Products sector have probably already heard of Academy Sports and Outdoors, Inc. (ASO) and Amer Sports, Inc. (AS). But which of these two companies is the be

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2

Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?
The disposition involved ~117,000 shares for a total value of $3.1 million. Traded shares represented 78% of the equity stake held directly before the filing.

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR